Laura Cadden says Aastrom Biosciences, Inc. (NASDAQ:ASTM) is one of the hottest biotech stocks priced under $5. The company hopes to use its proprietary Tissue Repair Cell (TRC) technology to revolutionise treatment for heart disease. And it is making good progress through the trial phases. Laura says Aastrom is poised to make 20% gains in six months

This from Today’s Financial News:

Investors expect President-Elect Obama to make good on his campaign promise to lift restrictions on federally funding human embryonic stem cell research. House Speaker Nancy Pelosi has vowed to introduce legislation for a regulatory framework necessary to enable expanded stem cell research.

Biotechnology experts consider both the regulatory framework (to underpin clinical trials) and the additional funding to be crucial to the future of the American bio-pharma industry. In fact, it could ring in a new era for American stem cell

...

Techne Corp. (TECH), a Zacks #1 Rank (“strong buy”), recently declared a quarterly dividend of 25 cents per share thanks to the company's solid performance. Techne is yielding 1.5%, which is well ahead of the industry average as most of the company's industry peers pay no dividend.

Company Description

Techne Corporation develops and manufactures biotechnology products as well as hematology calibrators and controls primarily in the United States and Europe. It is a holding company, operating two subsidiaries, Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.

R&D Systems is a specialty manufacturer of biological products. It has two operating divisions, which are Hematology and Biotechnology. The Hematology Division develops and manufactures hematology controls, which are used in hospitals and clinical laboratories to check the accuracy of blood analysis instruments. The Biotechnology Division develops and manufactures biotechnology products including purified

...

StemCells Inc. (Nasdaq: STEM) is a clinical-stage biotechnology company focused on the development and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver. Though controversial to many people, cell-based discoveries are important in medical and scientific advances.

The company’s HuCNS-SC product candidate (purified human neutral stem cells) is undergoing clinical trials to treat retinal and spinal cord damage and will soon be showcased to neuroscientists around the globe. StemCells today announced it will present the results of its retinal degeneration and spinal cord injury research program at the Society for Neuroscience Annual Meeting later this month in Washington, D.C.

As the world’s largest organization centered on advances in understanding the brain and nervous system, The Society for Neuroscience has established this annual meeting to allow neuroscientists all around the world to present, observe and discuss scientific breakthroughs, technology and advances. StemCells has established an ongoing

...

Throughout US history, the most dangerous time for stock markets has been when one party controls the White House and Congress, says Keith Fitz-Gerald. And when you account for inflation, it doesn’t really matter whether the Democrats or Republicans are in the driving seat.

This from Money Morning:

With the whipsaw trading we’ve seen of late, it appears that the U.S. financial markets are already chewing through the post-election honeymoon. I have to say that I, for one, am relieved that’s the case because it signals that the markets are already returning to normal.

I realize it may not feel that way, but there’s one very important thing to remember: We nearly always seem to receive the best news near, or at, market tops, and the worst news near, or at, market bottoms. Although that seems contradictory, it actually makes sense. And investors can take some solace in the fact that

...

Throughout US history, the most dangerous time for stock markets has been when one party controls the White House and Congress, says Keith Fitz-Gerald. And when you account for inflation, it doesn’t really matter whether the Democrats or Republicans are in the driving seat.

This from Money Morning:

With the whipsaw trading we’ve seen of late, it appears that the U.S. financial markets are already chewing through the post-election honeymoon. I have to say that I, for one, am relieved that’s the case because it signals that the markets are already returning to normal.

I realize it may not feel that way, but there’s one very important thing to remember: We nearly always seem to receive the best news near, or at, market tops, and the worst news near, or at, market bottoms. Although that seems contradictory, it actually makes sense. And investors can take some solace in the fact that

...

With the whipsaw trading we’ve seen of late, it appears that the U.S. financial markets are already chewing through the post-election honeymoon. I have to say that I, for one, am relieved that’s the case because it signals that the markets are already returning to normal. I realize it may not feel that way, but there’s one very important thing to remember: We nearly always seem to receive the best news near, or at, market tops, and the worst news near, or at, market bottoms. Although that seems contradictory, it actually makes sense. And investors can take some solace in the fact that the mounting tide of bad news is an important part of the bottoming process. Speaking of which, studies show that the most dangerous time for American markets (and U.S.-centric investors) is when one political party controls all the marbles. ...

BioHeart is a biotechnology corporation that develops devices designed to aid in the diagnosis, monitoring, and treatment of cardiovascular diseases. The company aims to improve heart disease sufferers’ quality of life, while attempting to reduce the normally exorbitant costs associated with cardiologic treatments.

In a press statement issued on Thursday, the company announced that it had received a United States Patent and Trademark Office Notice of Allowance for nine new patent claims, which pertain to using electrical signals to stimulate heart cell regeneration. BioHeart’s new technologies are a significant step forward in the field of cardiovascular treatment in that they utilize fundamental electro-chemical genetic instructions to “teach” undifferentiated stem cells to grow into heart muscle. This process will aid heart failure victims in regrowing damaged heart tissue, and could potentially save lives.

“The best way to predict the future is to create it,” said BioHeart’s director of surgical and clinical

...

Proteonomix Inc. is a biotechnology company dedicated to the development of cell therapies to treat a wide variety of diseases. Headquartered in Mountainside, New Jersey, their current research is focused on cosmetics, antiaging, and injury. Through their subsidiary ProteoDERM, INC., they are commercializing their various products.

Their new line of anti-aging skin care products is now hitting the market. Their ProteoDERM Inc.’s anti-aging products are their Matrix NC-138 system of products. They sell the Matrix NC-138™ (3%) Serum, and a Day Cream SPF-25, Night Cream, a Gentle Cleanser, and a Gentle Exfoliator.

Proteonomix is also developing a platform for the growth of contaminant-free human embryonic stem (hES) cell lines. They will then make these available to the research community. They anticipate the commercialization of this product in the fourth quarter of this year. Proteonomix is working with leading scientists at prestigious institutions around the world to make tailored stem cell

...

Congratulations on a long well fought race. Now, “fasten your seat belts, it’s going to be a bumpy ride.” The classic line from Betty Davis seems appropriate. No matter who won this race, they were inheriting a hell of a mess. No need to go into detail, just the list is daunting enough.

The debt, the deficit, two wars without end, the banking crisis, the mortgage crisis, the worldwide economic slow down, Social Security, a deadlocked partisan congress, health care, a tax system that everyone thinks is unfair, collapsing US auto manufacturers, jobs being exported at light speed, the defense of our northern and southern borders, a recession, still no energy policy, and what appears to be a complete collapse of our image abroad.

Why would anyone want this job? It’s beyond me. The real question is now that he has done what seemed like the impossible, how will it affect

...

Congratulations on a long well fought race. Now, “fasten your seat belts, it’s going to be a bumpy ride.” The classic line from Betty Davis seems appropriate. No matter who won this race, they were inheriting a hell of a mess. No need to go into detail, just the list is daunting enough.

The debt, the deficit, two wars without end, the banking crisis, the mortgage crisis, the worldwide economic slow down, Social Security, a deadlocked partisan congress, health care, a tax system that everyone thinks is unfair, collapsing US auto manufacturers, jobs being exported at light speed, the defense of our northern and southern borders, a recession, still no energy policy, and what appears to be a complete collapse of our image abroad.

Why would anyone want this job? It’s beyond me. The real question is now that he has done what seemed like the impossible, how will it affect

...